Aprogen Pharmaceuticals
Biopharmaceutical company focused on discovery and development of protein therapeutics and large-scale biologics manufacturing. Maintains an in-house manufacturing site (Osong) with integrated QA/QC and engineering functions. R&D capabilities include antibody engineering (multispecific and receptor-fusion formats), sequence-directed humanization, and recombinant fusion protein design. Manufacturing capabilities cover cell line development, upstream fed-batch and perfusion cultivation, downstream purification and impurity/virus control, and aseptic fill/finish. The organization is part of a corporate group that also operates materials and metals businesses providing surface engineering and specialty metals processing.
Industries
Nr. of Employees
small (1-50)
Aprogen Pharmaceuticals
Seongnam, Kyonggi-do, South Korea, Asia
Products
Pipeline portfolio (novel biologics and biosimilars)
Active development portfolio comprising novel biologic candidates (including multispecifics, receptor‑fusion constructs) and biosimilar programs at various stages of development.
Pipeline portfolio (novel biologics and biosimilars)
Active development portfolio comprising novel biologic candidates (including multispecifics, receptor‑fusion constructs) and biosimilar programs at various stages of development.
Services
End‑to‑end biologics manufacturing services including cell line development, upstream fed‑batch/perfusion cultivation, downstream purification and aseptic finish under cGMP operations.
R&D services for discovery and optimization of antibody therapeutics and recombinant fusion proteins, covering target discovery, lead design and optimization, sequence humanization, preclinical PK/PD and toxicology support.
Surface coating, cladding and repair services for industrial components using thermal spray, cold spray and PTA cladding methods; specialty metals trading and material processing.
End‑to‑end biologics manufacturing services including cell line development, upstream fed‑batch/perfusion cultivation, downstream purification and aseptic finish under cGMP operations.
R&D services for discovery and optimization of antibody therapeutics and recombinant fusion proteins, covering target discovery, lead design and optimization, sequence humanization, preclinical PK/PD and toxicology support.
Surface coating, cladding and repair services for industrial components using thermal spray, cold spray and PTA cladding methods; specialty metals trading and material processing.
Expertise Areas
- Antibody engineering for multispecific formats
- Sequence‑directed antibody humanization
- Recombinant fusion protein design
- Cell line development and cell banking
Key Technologies
- Bispecific antibody chain‑pairing engineering
- Sequence‑directed residue grafting
- Oligomerization domains for fusion proteins
- Fed‑batch and perfusion bioreactors
News & Updates
Corporate presentation materials posted to investor relations.
Company submitted the 54th business report for fiscal year 2024; filing referenced on investor relations with link to regulator filing.
Construction and commissioning of the Osong biologics manufacturing site completed; multiple manufacturing suites and downstream lines reported.
Reported receipt of national cGMP certification for biologics manufacturing.
Annual antibody drug substance production capacity reported at approximately 3,000 kg (company disclosure).
Company reports a multi‑dozen patent portfolio.
Corporate presentation materials posted to investor relations.
Company submitted the 54th business report for fiscal year 2024; filing referenced on investor relations with link to regulator filing.
Construction and commissioning of the Osong biologics manufacturing site completed; multiple manufacturing suites and downstream lines reported.
Reported receipt of national cGMP certification for biologics manufacturing.
Annual antibody drug substance production capacity reported at approximately 3,000 kg (company disclosure).
Company reports a multi‑dozen patent portfolio.